高度免疫抑制的髓状细胞与异性干细胞移植后的早期复发相关
Anne-Béatrice Notarantonio1,2, Allan Bertrand1, Romain Piucco3
1UMR 7365 CNRS, IMoPA, Université de Lorraine, 54000, Nancy, France.
Experimental hematology & oncology
|May 11, 2024
概括
干细胞移植后复发是常见的. 在患有急性髓性白血病或骨髓质综合征的患者中,免疫抑制性髓性衍生抑制细胞 (MDSC) 与复发风险相关. 准MDSC可以防止复发.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
背景情况:
- 全基性造血干细胞移植 (allo-HSCT) 提供了神经质恶性瘤的治愈潜力,但受到复发的限制.
- 复发后的allo-HSCT往往是由于恶性细胞逃避捐赠者的免疫反应,例如通过HLA变化或抑制性连接体的改变表达.
- 了解移植后的免疫功能障碍对于改善结果至关重要.
相关概念视频
Bone Marrow Sampling and Transplants
325
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
325
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Cell-mediated Immune Responses
68.2K
Overview
68.2K


